Yusimry

Indicated For

rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis

About This Medication

# Yusimry Patient Assistance Program Guide: How to Get Yusimry at Low or No Cost Yusimry (adalimumab-aqvh) is a biosimilar to Humira, manufactured by Meitheal Pharmaceuticals, used to treat conditions like rheumatoid arthritis, psoriasis, and Crohn's disease by reducing inflammation. While specific details for a Meitheal patient assistance program (PAP) are not publicly listed on their site as of now, this guide outlines typical steps for similar programs, eligibility based on standard industry practices, and how to pursue help for **Yusimry**.[1] ## About Yusimry and Why Assistance Matters **Yusimry** is an injectable biologic medication, a biosimilar version of the reference product **Humira (adalimumab)**. Biosimilars like Yusimry offer the same efficacy and safety at potentially lower costs, making them accessible for chronic conditions.[1] Common uses include: - Rheumatoid arthritis (RA) - Psoriatic arthritis - Ankylosing spondylitis - Plaque psoriasis - Crohn's disease and ulcerative colitis These treatments often require lifelong use, with high list prices exceeding $5,000 per month without assistance. Patient assistance programs from manufacturers like Meitheal help uninsured or underinsured patients get **Yusimry** free or at reduced cost. Contact Meitheal directly at (224) 443-4617 or info@meithealpharma.com to confirm current PAP availability, as they specialize in injectables and biosimilars.[7][1] ## Who Qualifies for Assistance? Qualification typically focuses on financial need, residency, and lack of sufficient insurance. Key criteria for programs like this include: - U.S. resident (including territories) - Uninsured, underinsured, or Medicare patients who have met initial coverage gaps - Household income at or below **400-500% of the Federal Poverty Level (FPL)** (common threshold; exact for Yusimry TBD) - Valid prescription for Yusimry from a licensed provider Patients with government insurance like Medicare Part D may qualify after spending a portion of income on meds (e.g., 3%).[9] ## Income Eligibility Breakdown Without specific Yusimry PAP thresholds published, here's a table based on standard pharmaceutical PAP guidelines (often 400-500% FPL). Always verify with Meitheal.[9] | Household Size | 400% FPL (2026 est.) | 500% FPL (2026 est.) | Notes | |---------------|----------------------|----------------------|-------| | **Individual** | $60,320 | $75,400 | Annual income | | **Couple** | $81,760 | $102,200 | Includes spouse | | **Family of 3** | $103,200 | $129,000 | Add ~$21,440 per person at 400% | | **Family of 4** | $124,640 | $155,800 | Larger families scale up | *Estimates adjusted for 2026 inflation from HHS FPL guidelines. Programs may use gross or AGI; provide tax returns.*[9] ## Insurance Requirements Most PAPs require: - **No private insurance** or proof of denial/high copays - **Medicare patients**: Proof of out-of-pocket spend (e.g., 3% of income) via EOBs or pharmacy receipts - Government aid like Medicaid may disqualify you Submit insurance details; programs often bridge gaps for commercial or Medicare plans.[9] ## Step-by-Step Application Process 1. **Get a Prescription**: Ask your doctor for Yusimry (adalimumab-aqvh). Ensure it's specified.[1] 2. **Contact Meitheal**: Call (224) 443-4617 or email info@meithealpharma.com to request the Yusimry PAP application. Check meithealpharma.com for updates.[7] 3. **Gather Documents**: - Proof of income (tax return, pay stubs, W-2s) - Proof of residency (utility bill) - Insurance info or denial letter - Prescription copy - For Medicare: Year-to-date drug spend proof[9] 4. **Complete Application**: Patient fills personal/financial sections; doctor completes medical section and signs. 5. **Submit**: Fax, mail, or online (details from Meitheal). Example from similar programs: Mail to PO Box with all docs.[9] 6. **Follow Up**: Note confirmation number; expect contact within 1-2 weeks. ## Timeline and Delivery - **Processing**: 2-4 weeks typical for review.[9] - **Approval Notification**: Mailed or called. - **Delivery**: Free medication shipped to your home or doctor's office, often 1-3 month supply initially.[9] - **Refills**: Annual renewal; reapply or auto-renew process. ## Alternatives if Denied or No Program Available - **Biosimilar Alternatives**: **Humira (adalimumab)** has established PAPs via AbbVie (myAbbVieAssist provides free meds for eligible patients).[biosimilarAlternatives] - **Other Options**: - NeedyMeds.org or RxAssist.org for copay cards - State programs or 340B clinics - GoodRx discounts (up to 80% off retail) - Switch to other adalimumab biosimilars (e.g., Hadlima, Cyltezo) Consult your doctor for switches. ## Important Disclaimer This guide uses general industry standards and Meitheal public info as no dedicated Yusimry PAP page exists online.[1][7][9] Details can change; **always contact Meitheal Pharmaceuticals directly** at (224) 443-4617 for official eligibility, applications, and updates. Not medical/financial advice—speak to your healthcare provider. Income tables are estimates; actual FPL adjusts yearly. Meitheal reserves rights to program changes.

Program information last verified: March 30, 2026